During the early years of the GLP-1 drug revolution, the food industry watched Ozempic almost like a storm gathering outside its factories. If millions of consumers eat less because drugs such as Wegovy, Ozempic, Mounjaro, or Zepbound suppress appetite, the math looks brutally simple for companies that sell food: less hunger could mean fewer snacks, smaller portions, lower consumption frequency and, eventually, lower revenue. Nestlé is now trying to turn that equation around. If those consumers are going to eat less, the company wants to develop products capable of capturing a larger share of what they do eat.

According to Reuters, the Swiss company is using artificial intelligence, nutritional science, and decades of research and formulations to develop products designed around the needs it has identified among consumers using GLP-1 medications. Stefan Palzer, Nestlé’s Chief Technology Officer, told Reuters that the company is analyzing clinical literature, nutrient combinations, and consumer behavior to develop solutions related to nutrition, hydration, and the maintenance of muscle mass during weight loss. Nestlé believes the shift should not be viewed solely as a threat to packaged food: “It is a huge opportunity for our company,” Palzer said.

What matters is not simply the product Nestlé may put on a store shelf tomorrow. The truly significant change is the emergence of a consumer whom the industry is beginning to consider distinct enough to warrant dedicated formulations, package sizes, claims, channels, and marketing strategies.

From Pharmaceutical Threat to Consumer Segment

Food companies’ initial fears had a commercial basis. The expansion of appetite-suppressing drugs raised concerns among investors about a potentially permanent deterioration in demand for packaged foods, beverages, and snacks. But Nestlé began working as early as 2023 on complementary products for these consumers and later launched Vital Pursuit in the United States, a frozen food line conceived with people using weight-loss treatments in mind. Its pizzas and bowls were formulated with higher levels of protein and other nutrients, along with portion sizes adapted to consumers whose appetite may have declined.

The strategy has continued to expand. Nestlé already sells Boost Advanced Nutrition Shake in the United States, a beverage containing 35 grams of protein marketed to support muscle health during weight loss; in Asia and Australia, it introduced Milo PRO High Protein. The company is also using collagen protein through Vital Proteins while researching nutrition related to muscle, hydration, and other changes associated with significant weight loss.

The shift is strategically important because it reframes the problem. Ozempic stops being merely a product that could potentially eliminate eating occasions and instead becomes an indirect creator of new ones.

It is the market’s familiar ability to build categories around social, technological, or medical change. Reduced sugar created oceans of light and zero products; high-protein diets fueled bars, drinks, and yogurts; the plant-based boom produced alternative milks, meat substitutes, and new sub-brands; keto turned a dietary regimen into packaging language. GLP-1 could become the next major commercial descriptor.

That does not necessarily mean we will see “for Ozempic users” splashed across every package. Segmentation can be far more subtle: greater nutritional density in smaller portions, more protein, fiber and hydration, easy-to-consume products, reduced formats, and messaging tied to muscle maintenance or nutrition during weight loss. The category could eventually become much larger than the medications that created it.

Food Genie: 120,000 Recipes Turned Into a Competitive Advantage

There is a second story hidden behind the products, and it may be even more significant competitively: artificial intelligence is beginning to transform how a multinational food company turns its historical knowledge into new products.

Nestlé developed Food Genie, an internal tool that allows scientists and product developers to work with a database of approximately 120,000 recipes, predict how different formulations may behave, and identify reformulation opportunities. The company is also using AI systems to analyze scientific literature, simulate consumer responses, and identify trends on social media.

The database of 120,000 recipes did not appear yesterday. Nestlé was already explaining in 2024 that it was using a connected tool capable of working with that volume of historical formulations to identify recipes that simultaneously meet nutritional, regulatory, taste, texture, cost, and sustainability requirements.

That is where a competitive advantage emerges—one that is difficult to replicate simply by purchasing an artificial intelligence license.

Models need information. Nestlé has decades of formulations, ingredient knowledge, research results, product behavior data, and industrial experience. AI can turn that corporate archive into a kind of computational memory capable of finding relationships that once required weeks or months of human work.

For large consumer-goods companies, the AI conversation is therefore beginning to move beyond making ads more cheaply or generating images in seconds. Its potentially most profitable application may be inside the laboratory: developing products faster.

If Food Genie can shorten innovation cycles, anticipate acceptance, or identify promising reformulations before every physical test is conducted, the impact could be seen directly in time-to-market, innovation costs, and the ability to respond to trends that emerge and disappear at ever-increasing speed. Nestlé is even testing AI-powered consumer simulations to anticipate how people might react to certain products or claims before they reach the market.

GLP-1 provides a perfect test case for that machinery because it represents a segment that is evolving even as companies are still trying to understand it.

Nestlé Is Not Alone: The Race for the GLP-1 Consumer Is Beginning

The phenomenon is starting to look less like an isolated Nestlé initiative and more like a new competitive arena within the food industry.

Danone launched Oikos Fusion in the United States, a drink aimed at consumers using weight-loss medications and formulated with whey protein and vitamin D to help support muscle maintenance. Conagra, meanwhile, began identifying Healthy Choice products as “GLP-1 friendly,” while Nestlé developed Vital Pursuit.

The race is revealing because the major companies are not trying to manufacture drugs; they are competing for the food ecosystem growing around them.

The same person who purchases a pharmaceutical treatment still eats breakfast, buys beverages, has dinner, consumes snacks, and visits supermarkets. What may change is how much they eat, what they tolerate, what they prioritize, and what they expect nutritionally from a smaller portion. For food companies, that changes the unit of value.

For decades, growth in many categories depended on selling more consumption occasions, larger sizes, or incremental volume. GLP-1 may push in the opposite direction: less volume, but greater nutritional density and potentially more added value per unit.

It is a commercial logic similar to premiumization, although built around different needs.

Mexico Could Become the Next Testing Ground

For Mexico, the phenomenon deserves attention even though many of the first purpose-built products are being launched in the United States and other markets.

Nestlé has a Mexican portfolio spanning infant nutrition, water, cereals, chocolate, coffee, culinary products, specialized nutrition, dairy, foodservice, and pet food. That breadth gives the company numerous categories from which to respond to changes in eating and nutrition habits.

The strategic implication goes far beyond whether Vital Pursuit will one day reach Mexican supermarkets.

If the use of GLP-1 medications continues to expand, companies such as Nestlé will have to ask how these consumers’ shopping baskets change: whether they buy smaller formats, increase their demand for protein, abandon certain categories, alter eating schedules, purchase more supplements, or replace indulgence with products perceived as nutritionally dense.

That information could affect innovation, category management, promotions, e-commerce, and retail media.

It could also create an entirely new advertising segment. Just as a brand can currently develop messaging for fitness, plant-based, or high-protein consumers, it could eventually build communications specifically around people undergoing medically supported weight-management journeys, although doing so would require particular regulatory, medical, and ethical care.

That is likely where an uncomfortable debate will emerge: how much of this category will respond to genuine nutritional needs, and how much will simply be marketing.

Do We Really Need Special Foods for GLP-1 Users?

The scientific and commercial answers are not the same.

Significant weight loss can include a reduction in lean mass, and maintaining adequate nutrition can become especially important when a person is consuming considerably less food. But that does not automatically mean every user needs to buy processed foods designed specifically for GLP-1. Reuters cited Amanda Avery, associate professor of nutrition and dietetics at the University of Nottingham, who noted that conventional foods such as fish, eggs, dairy products, beans, nuts, and legumes can also provide protein and other nutrients, sometimes at a lower cost.

That question is fundamental because it could determine the category’s credibility.

If “GLP-1 friendly” ends up functioning merely as a new label used to charge more for a product that was already high in protein, consumers may eventually perceive it as yet another marketing construct. If, on the other hand, companies can demonstrate through research that specific formulations, nutritional densities, portion sizes, or nutrient profiles genuinely make eating easier for consumers with particular needs, the category will have a stronger foundation.

The industry needs to resist the temptation to turn a medical treatment into an oversimplified food trend.

GLP-1 medications are treatments that should be managed within a clinical context; food can complement a diet, but it does not replace medical care or automatically turn a nutritional claim into a therapeutic solution.

That is precisely why Nestlé’s strategy is so interesting. Not because it has proven that the future of food will have the word Ozempic printed on the label, but because it shows that one of the world’s largest food manufacturers already considers this behavioral shift significant enough to reorganize research, artificial intelligence, and innovation around it.

For years, the industry sold products to consumers who wanted to lose weight. GLP-1 presents something different: selling products to consumers whose appetite is already being altered by medication. The difference may seem small, but it could reorganize entire categories.

The real business opportunity, then, would not be competing against Ozempic. It would be understanding what a person buys after they start using it. And if Nestlé, Danone, Conagra, and other companies succeed in turning those new needs into their own language of products, sizes, formulations, and claims, we may be witnessing the birth of something that barely existed as a marketing segment only a few years ago: the GLP-1 consumer.